Skip to main content

Table 3 Efficacy of the quadrivalent vaccine in preventing external genital lesions and AIN (per-protocol population)

From: Rome consensus conference - statement; human papilloma virus diseases in males

 

Giuliano [67]

Palefsky [71]

Goldstone [72]

Population

Per-protocol

Per-protocol

Per-protocol*

(16–26 years)

(16–26 years)

(16–26 years)

External genital lesions

90.4%;

  

(95%; CI: 69.2–98.1)

AIN

 

77.5%;

91.7%;

(95%; CI: 39.6–93.3)

(95%; CI: 44.6–99.8)

Anogenital warts

89.4%;

  
 

(95%; CI: 65.5–97.9)

  
  1. * Post-hoc analysis. AIN Anal intraepithelial neoplasia.